Functional & Integrative Genomics, Journal Year: 2025, Volume and Issue: 25(1)
Published: March 7, 2025
Language: Английский
Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)
Published: April 1, 2024
Abstract Lung cancer stands as the most prevalent form of globally, posing a significant threat to human well-being. Due lack effective and accurate early diagnostic methods, many patients are diagnosed with advanced lung cancer. Although surgical resection is still potential means eradicating cancer, usually miss best chance for treatment, even after may experience tumor recurrence. Additionally, chemotherapy, mainstay treatment has be chemo-resistant, resulting in poor clinical outcomes. The emergence liquid biopsies garnered considerable attention owing their noninvasive nature ability continuous sampling. Technological advancements have propelled circulating cells (CTCs), DNA (ctDNA), extracellular vesicles (EVs), metabolites, tumor-educated platelets (TEPs), tumor-associated antigens (TAA) forefront key biopsy biomarkers, demonstrating intriguing encouraging results diagnosis prognostic evaluation This review provides an overview molecular biomarkers assays utilized encompassing CTCs, ctDNA, non-coding RNA (ncRNA), EVs, TAAs TEPs. Furthermore, we expound on practical applications biopsies, including diagnosis, response monitoring, evaluation, recurrence monitoring context
Language: Английский
Citations
39
Journal of Experimental & Clinical Cancer Research, Journal Year: 2022, Volume and Issue: 41(1)
Published: Oct. 8, 2022
Although success was achieved in the therapy for a minority of advanced lung adenocarcinoma (LUAD) patients, anti-programmed death 1 (PD1) resistance found most LUAD patients. Here, we aimed to uncover potential role exosomal circular RNAs (circRNAs) refractory PD1 blockade. METHODS: circRNA sequencing and qRT-PCR were performed determine level circRNAs patients subsequently treated with anti-PD1. Then, RNA pulldown, immunoprecipitation, mass spectrometry, chromatin luciferase reporter assays, flow cytometry, sequencing, vitro vivo models used biological functions underlying mechanism circZNF451 anti-PD1 treatment resistance.circRNA identified up-regulation from progressive disease (PD) compared those partial remission (PR) after blockade therapy. Furthermore, elevated revealed be associated poor prognosis Additionally, demonstrated induce an anti-inflammatory phenotype macrophages exhaustion cytotoxic CD8+ T cells, enhanced TRIM56-mediated degradation FXR1 activate ELF4-IRF4 pathway macrophages. By transgenic mice, knockout ELF4 rescue immunotherapy efficacy tumors high circZNF451.Exosomal reshapes tumor immune microenvironment by inducing polarization via FXR1- axis is novel biomarker predicting sensitivity LUAD.
Language: Английский
Citations
53
Redox Biology, Journal Year: 2022, Volume and Issue: 56, P. 102430 - 102430
Published: Aug. 12, 2022
As a novel type of non-coding RNAs, covalently closed circular RNAs (circRNAs) are ubiquitously expressed in eukaryotes. Emerging studies have indicated that dysregulation circRNAs was related to neurological diseases. However, the biogenesis, regulation, function, and mechanism Parkinson's disease (PD) remain largely unclear. In this study, thirty-three differentially (DECs) were detected by RNA-sequencing between MPTP-induced PD mice model wild-type mice. Quantitative real-time PCR used determine RNA level DECs striatum (STR), substantia nigra pars compacta (SNpc), serum exosomes, it found circSV2b downregulated Then, functional experiments vivo employed explore effect PD. For dual-luciferase reporter, fluorescence situ hybridization (FISH), immunoprecipitation (RIP), pull-down, gene editing, CUT & Tag performed vitro confirm directly sponged miR-5107-5p alleviated suppression expression target Foxk1, then positively regulated Akt1 transcription. vivo, mechanistic analysis demonstrated overexpression resisted oxidative stress damage through ceRNA-Akt1 axis models. Taken together, these findings suggested miR-5107-5p-Foxk1-Akt1 might serve as key treatment, highlighted significant change exosomes. Therefore, be biomarker for diagnosis treatment
Language: Английский
Citations
48
Biomolecules, Journal Year: 2023, Volume and Issue: 13(6), P. 877 - 877
Published: May 23, 2023
Lung cancer is a commonly diagnosed and the leading cause of cancer-related deaths, posing serious health risk. Despite new advances in immune checkpoint targeted therapies recent years, prognosis for lung patients, especially those advanced stages, remains poor. MicroRNAs (miRNAs) have been shown to modulate tumor development at multiple levels, as such, miRNA mimics molecules aimed regulating miRNAs promise preclinical development. More importantly, miRNA-based can also complement conventional chemoradiotherapy, immunotherapy, reverse drug resistance increase sensitivity cells. Furthermore, small interfering RNA (siRNA) entered clinical trials favorable prospects. Therefore, this paper, we review treatment well adjuvant therapy present current state treatment. We discuss challenges facing application provide ideas novel therapies.
Language: Английский
Citations
43
Drug Resistance Updates, Journal Year: 2023, Volume and Issue: 72, P. 101016 - 101016
Published: Nov. 3, 2023
Drug resistance remains a major challenge in cancer treatment, necessitating the development of novel strategies to overcome it. Protein arginine methyltransferases (PRMTs) are enzymes responsible for epigenetic methylation, which regulates various biological and pathological processes, as result, they attractive therapeutic targets overcoming anti-cancer drug resistance. The ongoing small molecules targeting PRMTs has resulted generation chemical probes modulating most facilitated clinical treatment advanced oncology targets, including PRMT1 PRMT5. In this review, we summarize mechanisms underlying protein methylation roles specific driving Furthermore, highlight potential implications PRMT inhibitors decreasing promote formation maintenance drug-tolerant cells via several mechanisms, altered efflux transporters, autophagy, DNA damage repair, stem cell-related function, epithelial-mesenchymal transition, disordered tumor microenvironment. Multiple preclinical trials have demonstrated that inhibitors, particularly PRMT5 can sensitize drugs, chemotherapeutic, targeted therapeutic, immunotherapeutic agents. Combining with existing will be promising approach enhanced knowledge complex functions guide future may help identify new indications.
Language: Английский
Citations
25
Advanced Science, Journal Year: 2023, Volume and Issue: 10(36)
Published: Nov. 9, 2023
Abstract Ferroptosis, which is caused by iron‐dependent accumulation of lipid peroxides, an emerging form regulated cell death and considered a potential target for cancer therapy. However, the regulatory mechanisms underlying ferroptosis remain unclear. This study defines distinctive role ferroptosis. Inhibition CARM1 can increase sensitivity tumor cells to inducers in vitro vivo. Mechanistically, it found that ACSL4 methylated at arginine 339 (R339). Furthermore, R339 methylation promotes RNF25 binding ACSL4, contributes ubiquitylation ACSL4. The blockade facilitates effectively enhances ferroptosis‐associated immunotherapy. Overall, this demonstrates critical contributor resistance highlights as candidate therapeutic improving effects ferroptosis‐based antitumor
Language: Английский
Citations
24
Cell Death and Disease, Journal Year: 2024, Volume and Issue: 15(5)
Published: May 2, 2024
Abstract Cancer immunotherapy has rapidly transformed cancer treatment, yet resistance remains a significant hurdle, limiting its efficacy in many patients. Circular RNAs (circRNAs), novel class of non-coding RNAs, have emerged as pivotal regulators gene expression and cellular processes. Increasing evidence indicates their involvement modulating to immunotherapy. Notably, certain circRNAs function miRNA sponges or interact with proteins, influencing the immune-related genes, including crucial immune checkpoint molecules. This, turn, shapes tumor microenvironment significantly impacts response In this comprehensive review, we explore evolving role orchestrating immunotherapy, specific focus on mechanisms expression. Additionally, underscore potential promising therapeutic targets augment effectiveness Understanding could contribute development new strategies overcome improve patient outcomes.
Language: Английский
Citations
16
Trends in Pharmacological Sciences, Journal Year: 2024, Volume and Issue: 45(6), P. 520 - 536
Published: May 13, 2024
Language: Английский
Citations
9
Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)
Published: Oct. 30, 2024
Non-small cell lung cancer (NSCLC) remains an ongoing health concern, with poor treatment options and prognosis for many patients. Typically, individuals are detected at the middle terminal stages, resulting in medical results due to lack of initial diagnosis treatment. So, finding specific effective therapy is necessary. In addition, exosomes generally small lipid vesicles a diameter nanometer range that created released by different types. Exosomes have therapeutic potential through delivering bioactive compounds including microRNAs, siRNAs, proteins tumor cells, modifying microenvironment, promoting anti-tumor immune responses. recent years, exosome-based has become known as appropriate approach NSCLC This review offers overview possibility NSCLC, emphasis on mechanisms action, preclinical research, current clinical trials. Preclinical studies shown can decrease growth, metastasis, drug resistance models. Furthermore, trials looking safety efficacy therapies patients, offering important insights into their translational prospects. Despite promising evidences, significant obstacles remain, optimizing exosome isolation purification techniques, standardizing production strategies, developing scalable manufacturing processes. Overall, shows promise novel various methods treating enhance patient outcomes evolution
Language: Английский
Citations
9
Journal of Cellular and Molecular Medicine, Journal Year: 2025, Volume and Issue: 29(4)
Published: Feb. 1, 2025
ABSTRACT The family of protein arginine methyltransferases (PRMTs) occupies an important position in biology, especially during the initiation and development cancer. PRMT3 CARM1(also known as PRMT4), being type I methyltransferases, are key controlling tumour progression by catalysing mono‐methylation asymmetric di‐methylation both histone non‐histone substrates. This paper reviews functions potential therapeutic target value CARM1 a variety cancers. Studies have identified abnormal expressions several malignancies, closely linked to cancer progression, advancement, resistance treatment. Such hepatocellular carcinoma, colorectal cancer, ovarian endometrial These findings offer new strategies directions for treatment, enhancing effectiveness conventional treatment methods.
Language: Английский
Citations
1